Ivo Abraham is a professor in the Department of Pharmacy Practice, with joint appointments in the Department of Family and Community Medicine and the Clinical Translational Sciences program. He has also served on the faculty of Case Western Reserve University, University of Virginia, and (part-time) KU Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida, Rijksuniversiteit Groningen (Groningen, The Netherlands), New York University, University of Pennsylvania, Chang Gung University (Taiwan), and Hyogo University (Japan). He has lectured, consulted, and conducted research throughout the Americas, Europe, Asia, Australasia, and Africa.
A nurse by profession and a an outcomes, effectiveness, and economics researcher by trade, his research has been funded since 1984 by public funding agencies, foundations, and corporations. He coordinates the Senza Nome (Italian, “without a name”) research group, which, on the outcomes and effectiveness side, studies how variability in treatment regimens is associated with variability in patient outcomes; and how practicing in accordance with evidence-based guidelines translates into better patient outcomes. On the economics side, and focusing mainly on pharmacotherapeutics but also models of care, his group tries to reconcile four questions: what is the clinical effect? how much does it cost? is it worth it? and, can we afford it?
He has (co-)authored 520+ articles and 80+ chapters, and has (co-)edited 50+ books, monographs, and journal issues. Having been a member of several editorial boards, he currently serves as the Quantitative Methods Editor of JAMA Dermatology and as Editor-in-Chief of the Journal of Medical Economics.
In the US, he has served as chartered or ad hoc study section member for the NIH, NIMH, AHRQ, VA, and NSF since 1985. He has been an expert adviser to the Innovative Medicines and Innovative Health Initiatives, a joint 7.4 billion euro undertaking of the European Union and industry to stimulate research and innovation in human therapeutics, vaccines, as well as diagnostics and other technologies, from their inception in 2008. He has also served as expert to various public and private funding agencies in European, Asian, and North American countries.
His educational and scientific honors and awards include several named lectureships in the US and abroad; and an invitational research fellowship from the Japan Society for the Promotion of Science (2007-2008).
Representative Publications
Abraham I, Calamia M, MacDonald KM. Should a systematic review be required in a clinical trial report? Perhaps, but not yet. JAMA Network Open 2023;6:e234226. PMID: 36951867 DOI: 10.1001/jamanetworkopen.2023.4226
Abraham I, Lewandrowski K-U, Elfar JC, Li Z-M, Fiorelli RKA, Pereira MG, Lorio M, Burkhardt BW, Oertel JM, Winkler P, Yang H, León JFR, Telfeian AE, Dowling Á, Vargas RAA, Ramina R, Asefi M, De Carvalho PST, Delfino H, Moyano J, Montemurro N, Yeung A, Novellino P. Randomized clinical trials and observational tribulations: providing clinical evidence for personalized pain management care models. Journal of Personalized Medicine 2023;13:1044. PMID: 37511657 DOI: 10.3390/jpm13071044
Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I. Economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Review of Pharmacoeconomics and Outcomes Research 2023;23:309-316. PMID: 36637419 DOI: 10.1080/14737167.2023.2169135
Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. Cost-effectiveness and economic burden analyses of all first-line treatments of chronic lymphocytic leukemia. Value in Health 2022;25:1685-1695. PMID: 35537984 DOI: 10.1016/j.jval.2022.04.001
Obeng-Kusi M, Habila M, Roe D, Erstad B, Abraham I. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of Medical Economics 2021;24(Suppl 1):1-13. PMID: 34866541 DOI: 10.1080/13696998.2021.2002092
Alrawashdh N, Persky DO, McBride A, Sweasy J, Erstad B, Abraham I. Comparative efficacy of first-line treatments of chronic lymphocytic leukemia: network meta-analyses of survival curves. Clinical Lymphoma, Myeloma, and Leukemia 2021;21:e820-e838. PMID: 34274291 DOI: 10.1016/j.clml.2021.06.010
Alkhatib NS, Abraham I. The Six Delta platform for outcome-based pricing of pharmaceuticals. Journal of Medical Economics 2020;23:1209-1214. PMID: 32930629 DOI: 10.1080/13696998.2020.1824161
Oh YM, McBride A, Yun S, Bhattacharjee S, Slack M, Martin J, Jeter J, Abraham I. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. Journal of the National Cancer Institute 2018;110:1178-1189. PMID: 30380096 DOI: 10.1093/jnci/djy148
Aapro M, Ludwig H, Bokemeyer C, Gascón P, Boccadoro M, Denhaerynck K, Krendyukov A, Gorray M, MacDonald K, Abraham I. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Annals of Oncology 2016;27:2039-2045. PMID: 27793849 DOI: 10.1093/annonc/mdw309
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411. PMID: 27793849 DOI: 10.1093/annonc/mdw309
See also myNCBI bibliography at https://www.ncbi.nlm.nih.gov/myncbi/16g8m--tnXYk5/bibliography/public/ for publications since 1981.